Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 1/20 | 0.55 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.55 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.55 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20865036 | 0.88 | LMNA (0.54) | PTGER1PTGER4PTGER3PTGER2KMT2A | |
| SCHEMBL21982036 | 0.87 | FFAR1 (0.50) | FFAR1MAOBLTA4HFFAR4 | |
| SCHEMBL18986242 | 0.86 | MAOB (0.50) | PTGER1PTGER4PTGER3PTGER2MAOB | |
| SCHEMBL18986249 | 0.85 | LMNA (0.48) | KMT2ASMN1; SMN2MAOBLTA4HLMNA | |
| SCHEMBL18986192 | 0.85 | GPR132 (0.44) | SMN1; SMN2MAOBLTA4H | |
| SCHEMBL18986214 | 0.85 | GPR132 (0.44) | SMN1; SMN2MAOBLTA4H | |
| SCHEMBL18986273 | 0.85 | GPR132 (0.44) | SMN1; SMN2MAOBLTA4H | |
| SCHEMBL18986264 | 0.83 | RECQL (0.50) | SMN1; SMN2LTA4HLMNAL3MBTL1 | |
| SCHEMBL18986285 | 0.83 | GPR132 (0.55) | KMT2A | |
| SCHEMBL18986286 | 0.83 | GPR132 (0.55) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3687979-B1 | RESORCINOL DERIVATIVES FOR THEIR COSMETIC USE | OREAL (FR) | 2021-08-18 | — | — | EP | disclosed |
| US-20200246240-A1 | RESORCINOL DERIVATIVES FOR THEIR COSMETIC USE | L'OREAL (FR) | 2020-08-06 | — | — | US | disclosed |
| WO-2019063710-A1 | RESORCINOL DERIVATIVES FOR THEIR COSMETIC USE | L'OREAL (FR) | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246240-A1 | RESORCINOL DERIVATIVES FOR THEIR COSMETIC USE | KRT18, RARA, RBP4 | PTGER1 3241/4885PTGER4 1486/4885PTGER3 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.